Results 151 to 160 of about 1,056 (174)
Some of the next articles are maybe not open access.
Clinical and Experimental Dermatology, 2023
The pathogenesis of acquired perforating dermatosis remains unknown and management is challenging. Traditional treatment includes antihistamines, allopurinol, corticosteroids, retinoids, doxycycline, keratolytic agents and phototherapy but with limited efficacy in some patients. Recently, developments in biologics and small-molecule drugs have provided
Li-Wen, Zhang, Juan, Wu, Tao, Chen
openaire +2 more sources
The pathogenesis of acquired perforating dermatosis remains unknown and management is challenging. Traditional treatment includes antihistamines, allopurinol, corticosteroids, retinoids, doxycycline, keratolytic agents and phototherapy but with limited efficacy in some patients. Recently, developments in biologics and small-molecule drugs have provided
Li-Wen, Zhang, Juan, Wu, Tao, Chen
openaire +2 more sources
Learning from nemolizumab: A promising therapy for prurigo nodularis
Journal of Allergy and Clinical ImmunologyBrian S Kim
exaly +3 more sources
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire +1 more source
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire +1 more source
Nemolizumab (Nemluvio) for Atopic Dermatitis
The Medical Letter on Drugs and TherapeuticsNemolizumab (Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical ...
openaire +2 more sources
Aim Nemolizumab is a novel drug used for the treatment of chronic prurigo. Using the FDA Adverse Event Reporting System (FAERS) database, this research examined adverse drug events (ADEs) related to nemolizumab in order to pinpoint potential safety signals. Methods Nemolizumab was
Xiaoting Li, Weiling Chen, Xingwu Duan
openaire +1 more source
Xiaoting Li, Weiling Chen, Xingwu Duan
openaire +1 more source
Use of Nemolizumab in Refractory Scrotal Dysesthesia
JAMA DermatologyThis case report describes 2 patients with refractory scrotal dysesthesia treated with nemolizumab.
openaire +2 more sources
Lancet, TheBACKGROUND: Nemolizumab, an interleukin (IL)-31 receptor subunit α antagonist, inhibits the IL-31 pathway of itch and skin inflammation in atopic dermatitis.
Carrascosa, José Manuel +24 more
exaly +1 more source